[Therapeutic results with aclacinomycin A in recurring acute leukemias]

21 patients with relapsing or primarily chemotherapy resistant acute myeloid or lymphocytic leukemia were treated with Aclacinomycin A (ACM). 25 mg/m2 ACM were given i.v. daily for 7 consecutive days. 17 out of 21 patients are evaluable, 2 with acute lymphocytic and 15 with acute myeloid leukemia. Two of the patients with acute myeloid leukemia entered complete remission. A further patient, primarily resistant to adriamycin and daunorubicin, experienced a partial remission. None of the patients with ALL responded to ACM.